Agroforestry systems of high nature and cultural value in Europe: provision of commercial goods and other ecosystem services

Land use systems that integrate woody vegetation with livestock and/or crops and are recognised for their biodiversity and cultural importance can be termed high nature and cultural value (HNCV) agroforestry. In this review, based on the literature and stakeholder knowledge, we describe the structure, components and management practices of ten contrasting HNCV agroforestry systems distributed across five European bioclimatic regions. We also compile and categorize the ecosystem services provided by these agroforestry systems, following the Common International Classification of Ecosystem Services. HNCV agroforestry in Europe generally enhances biodiversity and regulating ecosystem services relative to conventional agriculture and forestry. These systems can reduce fire risk, compared to conventional forestry, and can increase carbon sequestration, moderate the microclimate, and reduce soil erosion and nutrient leaching compared to conventional agriculture. However, some of the evidence is location specific and a better geographical coverage is needed to generalize patterns at broader scales. Although some traditional practices and products have been abandoned, many of the studied systems continue to provide multiple woody and non-woody plant products and high-quality food from livestock and game. Some of the cultural value of these systems can also be captured through tourism and local events. However there remains a continual challenge for farmers, landowners and society to fully translate the positive social and environmental impacts of HNCV agroforestry into market prices for the products and services

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection